Krishnan Suma 4

What Happened Suma Krishnan, a reported 10% owner of Krystal Biotech (KRYS), sold a total of 25,000 shares in open-market transactions on March 4, 2026, generating approximately $6.58 million in proceeds. The sales were executed in multiple trades at prices ranging from about $256.68 up to $266.93 depending on the lot; the filing lists weighted-average prices for each block (individual block prices: $257.32, $258.54, $259.61, $260.37, $261.41, $262.35, $263.58, $264.64, $265.16, $266.42).

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (timely — within the typical 2-business-day requirement).
• Total shares sold: 25,000; approximate total proceeds: $6,580,269.
• Sale blocks and reported proceeds (examples): 6,000 sh @ $265.16 ≈ $1.59M; 4,852 sh @ $264.64 ≈ $1.28M; 3,667 sh @ $260.37 ≈ $954,762; smaller blocks range ~407–3,667 shares.
• Transaction code: S = Sale.
• Sales were made pursuant to a Rule 10b5-1 trading plan adopted Sept 4, 2025; plan effective Dec 4, 2025 and terminates Dec 4, 2026 (or earlier upon completion).
• Several footnotes state prices reflect weighted averages of multiple trades and provide the trade ranges; fuller breakdowns are available on request to the SEC/issuer/security holders.
• Shares owned after the transactions are not specified in this Form 4; certain related holdings (spouse and Krishnan Family Trust) are reported separately and disclaimed here except to the extent of pecuniary interest.

Context

• These were sales under a pre-arranged 10b5-1 plan, which is commonly used to execute trades at predetermined times and is viewed as routine rather than a direct signal of changed insider sentiment.
• As a 10% owner (not necessarily an executive), Krishnan is a significant shareholder; related holdings and transactions by her spouse and family trust are reported on separate filings.